BioSpace News Archive

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATL).

Milestone Scientific Inc. today announced the purchase of its CompuFlo ® Epidural and CathCheck ™ Verification System disposables from two additional leading hospitals, expanding the Company’s geographic footprint.

Tredegar Corporation reported that it has completed the sale of its approximate 18% ownership interest in kaleo, Inc pursuant to an agreement dated November 28, 2021, whereby Marathon Asset Management provided kaléo shareholders a full liquidity event opportunity.

PacBio today announced that its new HiFiViral SARS-CoV-2 solution has successfully sequenced and captured the entire genome of the SARS-CoV-2 Omicron variant lineage.

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.

Sanara MedTech Inc announced today that Zachary (“Zach”) B. Fleming has been appointed Chief Executive Officer effective January 1, 2022.

Novavax, Inc. and Serum Institute of India Pvt. Ltd. today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 8, 2022.

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).

Rational Vaccines, today announced preclinical research suggesting that the Company’s herpes simplex virus type 1 (HSV-1) vaccine candidate can protect against herpetic keratitis (HK), a leading infectious cause of blindness in developed countries.